TELETRADER News
7/30, 8:22 AM (Source: TeleTrader)
more TeleTrader news

AstraZeneca's revenue jumps 8% to $6.3B in Q2

AstraZeneca plc said on Thursday that its revenue in the second quarter of fiscal 2020 amounted to $6.3 billion, soaring 8% compared to the same period last year.

The pharmaceutical giant stressed its current priority is ensuring a "broad and equitable supply" of its COVID-19 vaccine globally at no profit during the pandemic. "Our company has mounted a significant response to COVID-19, with capacity to deliver over two billion doses of AZD1222 [vaccine], the accelerated development of our monoclonal antibodies and new trials for the use of Calquence and Farxiga to treat patients affected by the virus," CEO Pascal Soriot stated.

AstraZeneca also noted its reported earnings per share (EPS) in the second quarter stood at $0.58, while core EPS surged 32% year on year to $0.96.

Breaking the News / NP